Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

U.S. stock futures fall as President Donald Trump doesn't rule out a recession, and Oracle is set to report fiscal third-quarter results after the closing bell. Here's what investors need to know ...

SAN FRANCISCO, Feb. 28, 2025 /PRNewswire/ -- Novo Nordisk A/S (NYSE: NVO) is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental ...

Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed securities violations during the Phase 3 trial of CagriSema, known as REDEFINE-1. Investors who ...

Central to the lawsuit is the claim that the company's "optimistic forecasts" about CagriSema's effectiveness were unfounded. The suit also contends that the study's "flexible protocol," which ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate ...

BURLINGTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q4 2024 results, announced an increased quarterly dividend ...

Analysts see CagriSema and oral semaglutide as underappreciated catalysts and believe the company’s guidance remains conservative. "We simply believe in Novo’s guide as historically having been ...